Share this article
Share this article
ResearchAndMarkets.com's offering.
Profiles of 117 companies involved in developing diagnostics and therapeutics for Alzheimer's disease are presented along with 89 collaborations. The bibliography contains over 900 publications that are cited in the report.The report is supplemented with 48 tables and 27 figures.
Alzheimer's disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechanism of the disease and find a cure. The only drugs approved currently are acetylcholinesterase inhibitors but they do not correct the basic pathology of the disease, beta amyloid deposits and neurofibrillary tangles. Several new approaches emphasize neuroprotection as well.